Norges Bank
BMY.RT

Norges Bank’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Norges Bank’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-192,682
Closed -$133K – 2236
2020
Q4 		$133K Hold
192,682
– – ﹤0.01% 2106
2020
Q3 		$434K Hold
192,682
– – ﹤0.01% 2091
2020
Q2 		$690K Sell
192,682
-2,030,519
-91% -$7.33M ﹤0.01% 2035
2020
Q1 		$8.45M Sell
2,223,201
-2,932,920
-57% -$9.66M ﹤0.01% 1684
2019
Q4 		$15.5M Buy
+5,156,121
New +$13.4M ﹤0.01% 1659

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Norges Bank's BMY.RT Position: Q1 2021 in Review

Norges Bank sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 192,682 shares — an estimated $133K sold.

Norges Bank first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $15.5M in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Norges Bank reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Norges Bank sold 192,682 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $133K.
  • Norges Bank first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Norges Bank's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $15.5M in Q4 2019.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Norges Bank's 13F filing for Q1 2021, filed 7 May 2021.